Oramed Reports Positive End Of Phase 2 Meeting With FDA For Oral Insulin
Benzinga · 07/15 12:56
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phas
PR Newswire · 07/15 12:55
Insulin in Pill Form Would Be a Bonanza for Oramed
Drug trials suggest first commercial oral insulin capsule may be on the horizon Continue reading...
GuruFocus.com · 07/08 22:09
HC Wainwright & Co. Maintains Buy on Oramed Pharmaceuticals, Lowers Price Target to $16
HC Wainwright & Co. maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and lowers the price target from $20 to $16.
Benzinga · 06/22 11:51
ORMP: Positive Takeaways of Preliminary NASH Study Findings
Zacks Small Cap Research · 06/19 10:34
Oramed Pharmaceuticals shares are trading higher after the company announced the initial clinical trial results for the treatment of NASH with oral insulin.
Benzinga · 06/15 13:37
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin